Humanized Anti-Interleukin 6 Receptor Antibody Induced Long-term Remission in a Patient with Life-Threatening Refractory Autoimmune Hemolytic Anemia

Refractory autoimmune hemolytic anemia (AIHA) is associated with considerable rates of mortality. Interleukin 6 (IL-6) has been reported to play a role in the pathogenesis of AIHA. This report describes a patient with AIHA who was successfully treated with a humanized anti-human IL-6 receptor (IL-6R) monoclonal antibody (MoAb). He had experienced life-threatening AIHA and had received conventional therapy with corticosteroids, azathioprine, cyclophosphamide, cyclosporin A, melphalan, plasma exchange, and irradiation to his spleen. However, the patient’s symptoms and laboratory data did not show a sufficient improvement. Because his serum IL-6 level was elevated, we attempted to block IL-6 signaling by using a humanized anti-IL-6R MoAb, MRA.With 8 mg/kg of MRA administration every 2 weeks, the serum hemoglobin level gradually increased and normalized within 4 months. After 2 years of MRA treatment, the disease activity was well controlled without adverse reactions. Anti-IL-6R MoAb can be a novel and effective therapeutic agent for AIHA.

[1]  R. Weide,et al.  Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy , 2003, Lupus.

[2]  A. Schuerwegh,et al.  Influence of therapy with chimeric monoclonal tumour necrosis factor-alpha antibodies on intracellular cytokine profiles of T lymphocytes and monocytes in rheumatoid arthritis patients. , 2003, Rheumatology.

[3]  R. Price,et al.  Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. , 2002, Arthritis and rheumatism.

[4]  K. Yoshizaki,et al.  Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease. , 2002, Arthritis and rheumatism.

[5]  Lieping Chen,et al.  Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease , 2002, Nature Medicine.

[6]  A. Zanella,et al.  In vitro production of anti‐RBC antibodies and cytokines in chronic lymphocytic leukemia , 2002, American journal of hematology.

[7]  N Gupta,et al.  Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia , 2002, Leukemia.

[8]  S. Amadori,et al.  Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura. , 2002, Blood.

[9]  S. Perrotta,et al.  Anti‐CD20 monoclonal antibody (Rituximab) for life‐threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus , 2002, British journal of haematology.

[10]  A. Zanella,et al.  In vitro quantification of anti-red blood cell antibody production in idiopathic autoimmune haemolytic anaemia: effect of mitogen and cytokine stimulation. , 2000 .

[11]  M. Neurath,et al.  Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo , 2000, Nature Medicine.

[12]  T. Macdonald,et al.  Manipulation of cytokines in the management of patients with inflammatory bowel disease , 2000, Annals of medicine.

[13]  D Josef,et al.  The gel test: a new way to detect red cell antigen‐antibody reactions , 1990, Transfusion.

[14]  Thomas G. DeLoughery,et al.  Autoimmune Hemolytic Anemia , 2013 .

[15]  C. Hashimoto,et al.  Autoimmune hemolytic anemia , 1998, Clinical reviews in allergy & immunology.

[16]  T. Hirano.  Interleukin 6 and autoimmunity and plasma cell neoplasias. , 1992, Research in immunology.

[17]  S. Akira,et al.  Biological and clinical aspects of interleukin 6. , 1990, Immunology today.